Twitter

Posts Tagged ‘roche’


Roche clinches EU approval for breast cancer drug Perjeta

Roche said on Tuesday it clinched European approval for its breast cancer drug Perjeta, fuelling the company’s hopes that the drug will become the standard of care for an aggressive, incurable form of cancer.

Read More...

12 Billionaires Found at Swiss Drugmaker Roche

Feb. 22 (Bloomberg) — Roche Holding AG, the Basel, Switzerland-based drugmaker that manufactures the world’s best- selling cancer treatment, has minted at least 12 Swiss and German billionaires. Seven have never appeared individually on an international wealth ranking. Matthew G. Miller reports on Bloomberg Television’s “In The Loop.” (Source: Bloomberg)

Read More...

Seven Cancer Drug Billionaires Unmasked as Roche Surges

Roche Holding AG’s headquarters in Basel, Switzerland. Roche generated $48.5 billion in sales in 2012.

Read More...

FDA approves new use for Roche’s Avastin in colon cancer treatment

The US Food and Drug Administration on Wednesday approved the use of Roche’s Avastin for patients whose colorectal cancer has worsened despite previous treatment with the drug.

Read More...

Roche wins EU nod for breast cancer drug Perjeta

European health regulators recommended Roche’s breast cancer drug Perjeta for approval on Friday, cementing the company’s hopes that the drug will become the standard of care for an aggressive, incurable form of cancer.

Read More...

Roche breast cancer drug extends overall survival

Swiss pharma group Roche’s drug Perjeta significantly extended the lives of women with an aggressive and incurable form of breast cancer compared to a placebo, according to new data from a late-stage study presented on Saturday.

Read More...

One Year On Herceptin For Breast Cancer Ideal

Patients in early-stage HER2-positive breast cancer should remain on Herceptin (trastuzumab) treatment for one year, and not two years or six months, according to a final analysis of the Phase III HERA trial, pharmaceutical company Roche and the Breast International Group announced today…

Read More...

A Study of Vemurafenib Alone And Vemurafenib in Combination With GDC-0973 in Patients With Malignant Melanoma

Condition :   Malignant Melanoma Interventions :   Drug: vemurafenib;   Drug: Placebo;   Drug: GDC-0973 Sponsors :   Hoffmann-La Roche;   Hoffmann-La Roche Not yet recruiting – verified September 2012

Read More...

A Study of RO5520985 in Patients With Locally Advanced or Metastatic Solid Tumors

Condition :   Neoplasms Intervention :   Drug: RO5520985 Sponsors :   Hoffmann-La Roche;   Hoffmann-La Roche Not yet recruiting – verified September 2012

Read More...

An Observational Study of First-Line Maintenance MabThera/Rituxan (Rituximab) in Patients With Follicular Non-Hodgkin’s Lymphoma

Condition :   Follicular Lymphoma, Non-Hodgkin’s Lymphoma Intervention :   Sponsors :   Hoffmann-La Roche;   Hoffmann-La Roche Not yet recruiting – verified September 2012

Read More...